Integra LifeSciences completes $450 million notes offering and revamps $1.65 billion credit facility

Integra LifeSciences closed a private placement of $450 million of 9.500% senior secured notes that mature in 2033. At the same time it restated its credit agreement to an overall size of about $1.65 billion, consisting of a $600 million revolving facility, a $600 million term loan A and a $450 million term loan B. The net proceeds and new borrowings were applied to refinance the 2023 debt package and to cover related transaction costs.

The refinancing extends the company’s debt maturities and improves liquidity, which may affect its credit profile and borrowing costs. Investors should note that the old 2023 credit agreement, including a $1.3 billion revolver and a $775 million term loan, was terminated without early‑termination fees, reducing existing obligations.

  • 1Integra closed a private offering of $450 million aggregate principal amount of 9.500% senior secured notes due 2033.
  • 2The company amended and restated its credit facility to an overall size of approximately $1.65 billion.
  • 3The new credit facility includes a $600 million five‑year revolving credit line, a $600 million five‑year term loan A, and a $450 million seven‑year term loan B.
  • 4Proceeds from the notes and the new facilities were used to refinance existing debt and to pay fees and expenses.
  • 5The refinancing transactions were executed on October 19, 2026.
  • 6Integra terminated its 2023 credit agreement, which comprised a $1.3 billion revolver and a $775 million term loan, with no early‑termination fees.

Sources